Plain-English translation of NCT04472767 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether —a targeted cancer medication—works better when combined with two immune-boosting drugs ( and ) and a procedure called transarterial chemoembolization (TACE), which delivers chemotherapy directly into liver tumors. The study involves 35 people with hepatocellular carcinoma (a type of liver cancer) who are not candidates for surgery or transplant. Researchers want to see if this combination approach can help people live longer and keep their cancer from growing.
Most people diagnosed with advanced liver cancer cannot have surgery to remove their tumors. This combination of treatments—blending a targeted drug, immune-boosting medications, and a minimally invasive procedure—has shown promise in early testing, but researchers need to confirm whether it truly helps patients and is safe to use together.
You likely qualify if…
You likely don't qualify if…
You would receive the procedure (TACE) up to three times over 9–12 weeks, with timing adjusted based on your response. Between or after procedures, you would take a daily tablet of the medication and receive intravenous infusions of the two immune drugs on a set schedule (typically once every 3–4 weeks). You will have regular blood tests, imaging scans, and clinic visits to monitor how you're responding and watch for side effects. The entire treatment phase typically lasts several months, and you will be followed to track how long your cancer stays controlled.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States